%Toxicity associated with treatment
| Toxicity . | Grade . | Treatment group . | . | |
|---|---|---|---|---|
| . | . | DFMO-PCV n (%) . | PCV n (%) . | |
| Anemia | 3 | 8 (5.9) | 6 (4.3) | |
| 4 | 1 (0.7) | 0 | ||
| Granulocytopenia | 3 | 12 (8.8) | 21 (15) | |
| 4 | 12 (8.8) | 11 (7.9) | ||
| Leukopenia | 3 | 21 (15.6) | 24 (17.1) | |
| 4 | 2 (1.5) | 5 (3.6) | ||
| Thrombocytopenia | 3 | 16 (11.8) | 5 (3.6) | |
| 4 | 17 (12.6) | 3 (2.1) | ||
| Transaminase increase | 3 | 1 (0.7) | 2 (1.4) | |
| 4 | 3 (2.2) | 1 (bilirubin increase) (0.7) | ||
| Ototoxicity | 3 | 0 | 0 | |
| 4 | 0 | 0 | ||
| Nausea alone | 3 (2.2) | 4 (2.9) | ||
| Vomiting | 7 (5.2) | 5 (3.6) | ||
| Diarrhea | 8 (5.9) | 0 | ||
| Fatigue | 2 (1.5) | 1 (0.7) | ||
| Headache | 1 (0.7) | 1 (0.7) | ||
| CNSa | 2 (1.5) | 1 (0.7) | ||
| Infection | 2 (1.5) | 2 (1.4) | ||
| Toxicity . | Grade . | Treatment group . | . | |
|---|---|---|---|---|
| . | . | DFMO-PCV n (%) . | PCV n (%) . | |
| Anemia | 3 | 8 (5.9) | 6 (4.3) | |
| 4 | 1 (0.7) | 0 | ||
| Granulocytopenia | 3 | 12 (8.8) | 21 (15) | |
| 4 | 12 (8.8) | 11 (7.9) | ||
| Leukopenia | 3 | 21 (15.6) | 24 (17.1) | |
| 4 | 2 (1.5) | 5 (3.6) | ||
| Thrombocytopenia | 3 | 16 (11.8) | 5 (3.6) | |
| 4 | 17 (12.6) | 3 (2.1) | ||
| Transaminase increase | 3 | 1 (0.7) | 2 (1.4) | |
| 4 | 3 (2.2) | 1 (bilirubin increase) (0.7) | ||
| Ototoxicity | 3 | 0 | 0 | |
| 4 | 0 | 0 | ||
| Nausea alone | 3 (2.2) | 4 (2.9) | ||
| Vomiting | 7 (5.2) | 5 (3.6) | ||
| Diarrhea | 8 (5.9) | 0 | ||
| Fatigue | 2 (1.5) | 1 (0.7) | ||
| Headache | 1 (0.7) | 1 (0.7) | ||
| CNSa | 2 (1.5) | 1 (0.7) | ||
| Infection | 2 (1.5) | 2 (1.4) | ||
CNS, central nervous system.